Shelley Force Aldred is CEO and Co-founder of Rondo Therapeutics, an emerging preclinical stage biopharmaceutical company developing bispecific therapeutic antibodies that enable controlled activation of the immune system to fight cancer. In addition, Dr. Force Aldred is an adviser for Stanford’s SPARK translational medicine program and serves on the Board of Governors for the Stanford Medicine Alumni Association. Previously, Dr. Force Aldred served as VP for Preclinical Development at TeneoBio, a highly successful multispecific therapeutic antibody company. Dr. Force Aldred was formerly director of worldwide R&D for Active Motif following the acquisition of SwitchGear Genomics in 2013. In 2006, she co-founded SwitchGear Genomics, a venture-backed functional genomics platform company, and she served as its COO and Board Member. Prior to founding SwitchGear Genomics, Dr. Force Aldred was a Scientific Director on Stanford’s ENCODE Project and received her Ph.D. from Stanford University.



SPEAKING TOPICS

• Getting a start-up off the ground

• Entrepreneurship

†herapeutics development